CLARITY AND FOCUS FOR PATIENTS WITH SCHIZOPHRENIA

The first prescription digital therapeutic designed to treat schizophrenia

THRIVE™ for Schizophrenia

Pear Therapeutics has developed THRIVE™, a prescription digital therapeutic to be used in conjunction with medication for treating schizophrenia

Medication Plus Patient-Facing Smartphone Application

Clinician-Facing Web Interface

What is Thrive™?

  • THRIVE™ is a clinically validated prescription digital therapeutic applying evidence-based, multi-modal and reinforcement therapy. It is comprised of a patient-facing smartphone application and clinician-facing web interface.
  • THRIVE™ is a prescription digital therapeutic that provides 24/7, real-time patient monitoring and support.
  • THRIVE™ provides real-time interventions targeting positive symptoms of schizophrenia including hallucinations and delusions, and also provides support for schizophrenia-related mood disorders.

THRIVE™ as A Prescription Digital Therapeutic for Treating Schizophrenia

THRIVE™ enhances the efficacy of atypical anti-psychotics for schizophrenia

A 30-day trial of THRIVE™ shows significant reduction in the following:

thrive_graph1
thrive_graph2
thrive_graph3
thrive_graph4

 

  • 33 patients on anti-psychotic medications were given access toTHRIVE™ and their symptoms were evaluated for 30 days.
  • After 30 days of therapy, patients showed an average 8% reduction in Positive and Negative Syndrome Scale (PANSS).
  • Patients were highly satisfied withTHRIVE™, interacting with the application an average of 5.2 times per day.  63% of the use was initiated by patients.
Ben-Zeev et al. Schizophrenia Bull. 2014.

Pear's Academic Partners are Currently Conducting Additional Trials Examining Efficacy in Schizophrenia

  • Currently concluding a 3-year multi-site/multi state study in which 400+ patients with schizophrenia will receive THRIVE™ for 6 months of treatment post-discharge from an episode requiring hospitalization
  • In 2016, Pear’s academic partners will conduct a randomized controlled trial (RCT, n=40 people with schizophrenia) of THRIVE™ vs Treatment as Usual
  • In 2016, Pear’s academic partners will start a 2.5 year RCT comparing THRIVE™ to a clinic-based group intervention (n=160 people with severe mental illness)

For more information, please contact us

Contact Us

THRIVE™ is not yet available for sale in the United States